Summary Abnormal CA 15-3 antigen levels are found in the serum of most patients with advanced breast carcinoma. Elevations of this marker are less frequently seen in other malignancies. Circulating CA 15-3 levels might be useful in the differential diagnosis of the primary site of cancer. We studied the levels of CA 15-3 in 500 patients with different non-mammary cancers. Elevations of CA 15-3 (>40Urml-1) were observed in all types of epithelial malignancies, especially in ovarian (46%), respiratory (26%) and liver (30%) carcinomas. Abnormal values were observed in some patients with haematological malignancies and sarcomas, but not in melanoma or neurological tumours. CA 15-3 antigen levels correlated with the extent of non-mammary malignant tumours. Patients with locoregional cancer had a significantly smaller proportion of elevations of the antigen than those with distant metastases (12% versus 35%, P<0.001). In particular, elevated CA 15-3 levels were observed in 70% of patients with metastatic ovarian cancer. Liver involvement by cancer did not produce more elevations of CA 15-3 than metastases to other organs (32% versus 39%). Simultaneous determination of circulating CA 15-3 and CA 125 antigens in 58 patients with cancer of the ovary showed that CA 15-3 is elevated in some cases of ovarian carcinoma with non-elevated CA 125, and that CA 15-3 and CA 125 are distinct antigens. We conclude that circulating CA 15-3 antigen levels can be found elevated in virtually all types of cancer, particularly when distant metastases are present. Therefore, CA 15-3 levels should not be used in the differential diagnosis of the primary site in patients with metastatic malignancies of unknown origin. Evaluation of CA 15-3 levels may enhance the sensitivity of CA 125 in monitoring the course of ovarian carcinoma.
CA 15-3 is a cancer-associated antigen that is found in the serum of more than 70% of patients with advanced breast carcinoma and in a much lower proportion of patients with non-mammary malignancies (Gion et al., 1986; Hayes et al., 1986; Jager et al., 1986; Paulick et al., 1986; Pons-Anicet et al., 1987) . Circulating CA 15-3 antigen levels might be useful in distinguishing breast carcinoma from other malignancies. However, the expression of circulating CA has not been tested in all types of malignancies, and factors that might be relevant to CA 15-3 levels in non-mammary cancers such as disease extent or liver involvement have not been evaluated. We studied the levels of the antigen CA 15-3 in a series of 500 patients with different stages of epithelial and nonepithelial tumours, and compared the levels of CA 15-3 and CA 125 antigens in patients with ovarian carcinoma. The results indicate that elevated CA 15-3 antigen levels can be observed in all types of cancer and that, in patients with non-mammary malignancies, the levels of CA 15-3 correlate with the presence of metastatic disease, although independently of liver involvement. CA 15-3 antigen levels, therefore, should not be used in the differential diagnosis of the primary site in advanced malignancies. The results further show that antigen CA 15-3 is distinct from ovarian carcinoma-associated antigen CA 125.
Patients and methods
We studied the levels of the antigen CA (Ruibal et al., 1987 
Results
In Table I we show the distribution of CA 15-3 levels in patients with non-mammary cancers. We also show the results obtained in 275 apparently healthy blood donors and in 173 patients with metastatic breast cancer (Colomer et al., 1988 , and unpublished data). The percentage ofelevated values of CA 15-3 and the mean levels of the marker in the whole group of patients with non-mammary malignancies were significantly higher than those of the control group (P<0.01 and P=0.001, respectively), and significantly lower than those of patients with metastatic breast cancer (P<0.01 and P=0.0001, respectively). Three groups of patients showed CA 15-3 levels higher than healthy subjects: primary liver cancer (P=0.008), respiratory cancer (P<0.0001) and ovarian cancer (P<0.0001). Patients with locoregional cancer, distant non-liver metastases and liver involvement all presented CA 15-3 levels ,significantly higher than healthy subjects (P= 0.009, P <0.0001 and P <0.0001, respectively). Patients with distant metastases had higher levels of CA 15-3 than patients with locoregional disease (P<0.001), but no significant differences were appreciated between patients with or without liver involvement.
Abnormal CA 15-3 values were particularly observed in patients with primary liver cancer (48, 50, 52, 62, 70, , respiratory cancer -9/59 with locoregional disease (41, 49, 47, 60, 62, 64, 65, 76, , 10/21 with distant non-liver metastases (42, 44, 45, 50, 61, 68, 90, 92, 110, , and 6/14 with liver metastases (42, 48, 193, 200, 200 , 1,200Uml -1) -and ovarian cancer -1/8 with local disease (47 U ml-1), 12/30 with regional disease (43, 44, 51, 70, 75, 80, 85, 90, 141, 145, 147, Colomer et al., 1988) . breast carcinoma. In patients with breast cancer, CA 15-3 CA 15-3 has been found useful in monitoring the course of antigen levels correlate with the presence of metastases advanced breast cancer and in the post-surgical follow-up of and, as we have recently demonstrated, patients with breast carcinoma Molina et with the extent of metastatic involvement (Colomer et al., al., 1986; Sturm et al., 1987; Yoshimoto et al., 1987; 1988) . In the present study, we have shown that 70% of Colomer et al., 1988) . CA 15-3 levels might be useful in patients with metastatic ovarian carcinoma have elevated distinguishing breast carcinoma from other types of CA 15-3 antigen levels, which is very similar to the 75% of malignant disease. Elevated CA 15-3 antigen levels have been elevations that we observed in patients with metastatic breast observed in selected cases of epithelial carcinomas (Gion et carcinoma (Colomer et al., 1988) , and that very high values al., Hayes et al., 1986; Jager et al., 1986; Molina et (Hilkens et al., 1984; Kufe et al., 1984 ; Friedman the sensitivity in monitoring patients with ovarian et al., 1986) . Ninety-three percent of 140 human epithelial carcinoma. The antigens detected individually by monoclonal primary tumours reacted with monoclonal antibodies 115D8 antibodies 115D8 and DF3 have been similarly found to be or DF3, including breast, ovarian, lung and also colon and distinct from antigen CA 125 and to increase moderately the gastric carcinomas (Zotter et al., unpublished data) . The sensitivity of CA 125 in ovarian carcinoma (Koldovsky et individual antigens detected by antibodies 115D8 and DF3, al., 1986; Sekine et al., 1985) . however, as well as CA 15-3 antigen, are detected in the In summary, the antigen CA 15-3 can be elevated in the serum of a comparatively low percentage of patients with serum of patients with epithelial and non-epithelial nonnon-mammary epithelial tumours  mammary malignancies. In addition, CA 15-3 levels correlate Es with the presence of metastatic disease biut not with liver involvement by tumour. Circulating CA 15-3 antigen levels should not be used in the differential diagnosis of patients with metastatic cancer. Finally, CA 15-3 is an antigen distinct from CA 125 that might increase the sensitivity in monitoring patients with ovarian carcinoma.
